key: cord-1040304-m77ru69h
authors: Mehta, Asmita A.; Haridas, Nithya; Belgundi, Preeti; Jose, Wesley M.
title: A systematic review of clinical and laboratory parameters associated with increased severity among COVID-19 patients
date: 2021-02-20
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.02.020
sha: d39a789eeee17e032ec57989f5569157685b4ec6
doc_id: 1040304
cord_uid: m77ru69h

BACKGROUND AND AIMS: Corona virus disease 2019 (COVID-19) has been an extremely difficult pandemic to contain and it has affected more than 148 countries worldwide. The main aim of this systematic review is to provide a comprehensive summary of clinical and laboratory parameters that are associated with and indicative of increased severity among COVID-19 patients. MATERIAL AND METHODS: All the available data from high-quality research articles relevant to the epidemiology, demographics, trends in hospitalization and outcomes, clinical signs and symptoms, diagnostic methods and treatment methods of COVID-19 were retrieved and evaluated for inclusion. RESULTS: As per our review, the mean age of patients in the severe group was 59.3 years compared to 46.5 years in non severe group. COVID-19 was more severe among men than women. Clinical presentation was variable among different studies. and dyspnea was the factor indicating severe disease. Laboratory parameters associated with increased severity were lymphopenia <0.8 × 10(9)/L, thrombocytopenia 100 × 10(9)/L, leucocytosis TC > 11 × 10(9)/L, procalcitonin >0.5 ng/mL, d dimer >2 mcg/mL, aspartate transaminase elevation >150U/L, LDH >250U/L. CONCLUSION: This systematic review suggests that COVID-19 is a disease with varied clinical presentation and laboratory parameters. The commonest clinical symptoms were fever, cough and dyspnea. The laboratory parameters associated with severe disease were lymphopenia, elevated LDH, D dimer and Procalcitonin.

All the studies that included confirmed COVID-19 cases and studied factors affecting its severity were included in the analysis. The studies were either original article or case series on COVID-19 patients which were published or accepted (and in pre print form) from December 2019 to March 2020 in English literature.

The investigator (MA) performed the literature search and extracted the data with three other investigators (B P, W J and H N) from included studies. We resolved disagreements with a discussion and consensus. We extracted the following variables:

author, date, age, gender, number of participates in severe and non-severe groups. We also included data on the prevalence of clinical symptoms such as fever, cough, fatigue, and dyspnoea and presence of co morbidities e.g: hypertension, diabetes, respiratory system disease, and cardiovascular diseases. The flow of the study selection is shown in Fig:1 . [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] We have enlisted the included studies and their type in table: 1.

We have included all the studies on patients with confirmed diagnosis of SARS Corona virus -2 by RT PCR and published in English literature up to 4th April 2020. Details of clinical features like baseline demographics, symptomatology, presence of co morbidities, and laboratory investigations and clinical management were gathered. Patients with more severe disease were compared with those with non severe disease.

We included all the studies on COVID-19 patients published in English language in indexed journals.

The study by W Guan J [6] et al, reported COVID-19 affected patient's mean age to be 45 years (35-58). The mean age of patients with severe COVID-19 disease was 52 years (40-65) in comparison to mean age of 45 years in those with non severe disease. The age distribution of COVID-19 patients in study by Dawei Wang et al [9] was 56 years (42-68), 66 years (57-78), and 51 years (37-62) years respectively for overall group, severe and non severe patients respectively. Jin-jin Zhang et al [12] described mean age of 57 years in entire cohort, while, it was 51.5 years (26-78) and 62 years in non severe and severe group respectively. According to Huang et al [5] and Yu Shi et al [15] , SARS-CoV-2 / COVID-19 seems to have a predilection for the elderly male population. According to the study published by Fei Zhou et al [16] , the mean age of non survivors was 69 (63-76) while among survivors it was 52(45-58) years. Wei Liu et al [17] showed that mean age of population which had progressive disease was 66 years while it was 37 years for those who had stable disease. As per the study by Xiaobo Yang et al [18] , the survivors mean age was 51.9 year compared to 64.6 years among non survivors. These findings are summarized in Figure 1 .

In general, COVID-19 was more severe in males compared to female population. In a study reported by Xiaobo Yang et al only 46% patients were women [18] . These results for multiple studies are summarized in Figure 2 .

Fever was the most common symptom followed by dyspnoea and productive cough. W Guan Z et al [6] studied 1096 patients with COVID-19 in China. Clinical symptoms noted were fever (3.51%), cough (67.8%), expectoration (33.8), dyspnoea (18.7) , muscle ache (14.9) and sore throat (13.9) . In severe cases, dyspnea was present in 37.6% of the patients.

Huang et al [5] analyzed 41 patients of COVID-19, of which 40 (98%) had fever and 31 (76%) had cough. Of the 40 patients with fever, 13 were in managed in intensive care units and 27

were in treated in the wards. Other symptoms in COVID-19 confirmed cases were expectoration (39%), dyspnoea (40%) muscle ache (43%) fatigue (16%), headache (10%), J o u r n a l P r e -p r o o f gastrointestinal discomfort (2%), shortness of breath (SOB) (55%) and [5] . Huang et al noted that the average time from onset of symptoms to hospitalization was 8 days.

Dawei Wang et al [9] in a study of 138 patients reported that the median time from starting of symptom to hospital admission was about 7 days (4-8) and time from hospital admission to ARDS was 8 days (6) (7) (8) (9) (10) (11) (12) . They found 136 (98.5%) had fever, 36 (26%) required ICU. Fever was the most common symptom, followed by cough 69.6%, expectoration 26.8%, dyspnoea 31.2%, sore throat in 17.4% and muscle ache in 34.8 % of patients. Eighty two (55%) patients recuperated while 68 (45%) patients succumbed to the disease.

Jin-jin Zhang et al [12] studied 140 patients and commonest clinical symptoms were fever (91.7%), cough (75%) and dyspnoea (36.7%). Other clinical symptoms and their relationship with severity are shown in Figure 3 . Fei Zhou et al [14] analyzed 191 patients and fever (94%), cough (79%) expectoration (23%) and muscle ache (15%) were commonest symptoms in their study too. Time from first symptom to hospital admission was 11 days (8) (9) (10) (11) (12) (13) (14) . Time from hospital admission to death / discharge was 21 days (17) (18) (19) (20) (21) (22) (23) (24) (25) . Forty two (21.98%) patients died of the disease. Yang et al [18] analyzed 52 cases of RT-PCR confirmed COVID-19 in Wuhan and commonest symptoms found were fever (98%), cough (77%), and SOB (63.5%) [18] . However, a few of their patients had atypical symptoms like nausea, vomiting (4%) and

The clinical signs and symptoms from different studies and their occurrence as per severity are summarized in Table 2 .

Lymphopenia was common among all patients irrespective of the severity status.. Leucocytosis was common in the severe group as compared to the non severe group. Thrombocytopenia was also more commonly seen in the severely affected group except in the report by Hauang et al. [5] Elevation of procalcitonin and Serum LDH also showed a similar trend with higher incidence in the severely affected patients. Studies by Huang et al [5] and Zhou et al [16] showed variable response in elevation of Ferritin between severe and non severe group. Majority of the studies showed a larger percentage of J o u r n a l P r e -p r o o f severely ill patients had raised d-dimer levels. A larger percentage of the severely affected patients across all studies had raised transaminases.

Bilateral pneumonia was seen among the study population irrespective of the severity of the disease. But it was not as common among the non severe patient in the study by W.Guan et al [8] . The detail of laboratory parameters and their relation with severity is shown in Table: 3.

Patients affected with COVID-19 were found to have multiple co-morbidities. Most studies reported higher morbidity and mortality with COVID-19 among patients with co-morbid conditions. Hypertension and diabetes mellitus was the commonest of comorbidities..

Other common co-existent diseases included malignancies, respiratory disorders, chronic kidney disease and chronic liver disease. As shown in Figure 3 , underlying hypertension, cardiovascular disease and respiratory system disease were common co morbidities associated with severe disease.

COVID 19 has become notorious for its respiratory system involvement in form of pneumonia and the subsequent requirement of ventilation support (Fig: 4) W.Guan et al [8] observed that 32.4% of severely ill patients required non COVID-19 has taken the entire world in its grip. As of April 23, 2020 more than 26,28,527 confirmed COVID 19 cases and 1,82,424 deaths have been reported worldwide. [19] A cluster of 41 cases of pneumonia who gave history of visit to local wild animal market within 30 days of infection was reported from Wuhan, Hubei province, China. [20] It was first identified and announced as a new corona virus (2019 nCoV) by a scientific team of Chinese Academy of Engineering [21] . COVID-19 has become a significant clinical threat to the general population and health care workers worldwide. [2.22] Unfortunately, knowledge about the novel virus is limited.. Hence, the public needs to be educated to garner information from reliable sources such as the world health organization (WHO) [2] . A pandemic like COVID-19 exerts severe stress on every aspect of the society, and poses serious threat to international health and the economy. [2.3.22] This systematic review aimed to elucidate the risk factors associated with increased severity of COVID-19, so that the countries that are still in the early phase of transmission can use the data and apply the information for better management of their patients and resources.

The current systematic review can also be used to develop severity scoring for COVID-19.

Final analysis mainly included 8 studies which described two groups in COVID-19, severe and non severe group. We noted that the mean age of severe group was 59.3 years compared to 46.5 years in non severe group. Sufficient studies have endorsed the same [4-18.] Our review also confirmed that men were affected more and had more severe disease compared to women.

We could not find any association between various clinical symptoms and their association with increased severity. As shown in table 3, we could not find any particular symptom which could be more likely to represent more severe disease except dyspnoea which was consistently more common in severe group in all the studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The studies included in present review did not show any incidence of loss of smell and taste as one of the symptom, which recently has come across from many individual case series. [19] Laboratory parameters associated with more severe disease were lymphopenia <0.8x 109/μL, thrombocytopenia <100x 10 9 /L, leucocytosis TC >11 x10 9 /L procalcitonin >0.5, d J o u r n a l P r e -p r o o f dimer > 2 ng/mL, aspartate transaminase (AST) elevation > 150 units/L), LDH > 250U/L.

There were very few studies which showed elevated ferritin and trop T. Elevated Ferritin, LDH, CRP, AST, d dimer can be attributed to cytokine storm which has been reported in COVID-19 patients. [23] Our review also found that severe COVID-19 cases occurred mostly in people with comorbid conditions like hypertension, cancer and diabetes. Many of them developed various post COVID-19 complications e.g: coagulation activation, cellular immune deficiency, hepatic and kidney injury, secondary bacterial infection and myocardial injury. It has been understood that lymphopenia and sustained inflammation seen in patients with severe disease and death are most likely secondary to antibody-dependent enhancement (ADE) of COVID-19 due to previous exposure to other corona viruses [23, 24] . A similar pattern was also seen in patients who had SARS epidemic in 2003 [25] .

We found that patients requiring any form of ventilation generally belonged to the severe group. The studies included did not show sub group analysis and thus we could not confirm whether mechanical ventilation improved the survival.. ARDS caused by viral pneumonia and role of mechanical ventilation has been published by many studies with similar results. [25] [26] [27] In general, the ARDS in viral pneumonia occurs in more severe patients [25] [26] [27] So, the survival rate among the patients requiring mechanical ventilation was lower. [25, 28] Further, review is needed to find out the survival rate among the ventilated patients and factors affecting the survival so that judicious use of ventilator can be done in resource limited setting.

The COVID-19 is rapidly evolving clinical condition and the data and available information changes every day. The studies included had heterogeneous distribution of population, and only two of them actually studied comparison among survivors and non survivors, and 4 of them addressed the issue of severe and non severe disease. Conclusion:

The present systematic review concludes that COVID-19 is lethal disease with varied clinical presentation and laboratory abnormalities. The commonest clinical symptoms were fever, cough and dyspnea. The laboratory parameters associated with severe disease J o u r n a l P r e -p r o o f were lymphopenia, elevated LDH, D dimer and procalcitonin > 0.5ng/mL. It is necessary for health care workers to identify those patients early, who are likely to have severe form of COVID-19 and take proactive steps to reduce morbidity and mortality, until effective therapeutics and vaccines are made discovered.

J o u r n a l P r e -p r o o f Table: 1 Table showing 

The PRISMA statement for reporting systemtatic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-72

Clinical features of deaths in the novel coronavirus epidemic in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of coronavirus disease 2019 in China

Novel Coronavirus Pneumonia Emergency Response Epidemiology Team The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in

Comorbidity and its impact on 1590 patients with COVID-19 in China: A Nationwide Analysis

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

How to protcect yourself from COVID-19

Coronavirus disease 2019: coronaviruses and blood safety

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model

Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study

Use of High-Flow Nasal Cannula Oxygen Therapy in Subjects With ARDS: A 1-Year Observational Study